Please login to the form below

Not currently logged in
Email:
Password:

Metrion Biosciences establishes scientific advisory board

The board will provide scientific oversight and strategic advice to Metrion

Contract research organisation and drug discovery business Metrion Biosciences has established a scientific advisory board, which will provide strategic scientific guidance to the company.

The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

Dr Reynolds has served in numerous positions at Merck, Lundbeck and Pfizer.

Dr Tom Colatsky also joins the board following over 30 years of drug discovery experience, including seven years in senior US Food and Drug Admistration positions.

The board will also comprise of Professor Annette Dolphin, Professor Chris Denning and Marc Rogers, who is currently chief scientific officer at Metrion.

20th February 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics